"{\"compartment_location\":\"Blood-Lymph\", \"variable_name\":\"CTLA4_mabB\", \"units\":\"mole\", \"variable_definition\":\"Anti-CTLA-4 antibody in the blood\"}"
"{\"compartment_location\":\"Blood-Lymph\", \"variable_name\":\"CTLA4_mabB_ugml\", \"units\":\"\u00b5g/ml\", \"variable_definition\":\"Serum concentration of Anti-CTLA-4\"}"
"{\"compartment_location\":\"Blood-Lymph\", \"variable_name\":\"PD1_mabb\", \"units\":\"mole\", \"variable_definition\":\"Anti-PD-1 antibody in the blood\"}"
"{\"compartment_location\":\"Blood-Lymph\", \"variable_name\":\"PDL1_mabb\", \"units\":\"mole\", \"variable_definition\":\"Anti-PD-L1 antibody in the blood\"}"
"{\"compartment_location\":\"Blood-Lymph\", \"variable_name\":\"PDL1_mabB_ugml\", \"units\":\"\u00b5g/ml\", \"variable_definition\":\"Serum concentration of Anti-PD-L1\"}"
"{\"compartment_location\":\"Blood-Lymph\", \"variable_name\":\"PD1_mabB_ugml\", \"units\":\"\u00b5g/ml\", \"variable_definition\":\"Serum concentration of Anti-PD-1\"}"
"{\"compartment_location\":\"Blood-Lymph\", \"variable_name\":\"Effector_TB\", \"units\":\"cell\", \"variable_definition\":\"Effector T cells that have been generated from all the lymph nodes considered that have migrated into the blood\"}"
"{\"compartment_location\":\"Blood-Lymph\", \"variable_name\":\"Effector_T_TOTAL\", \"units\":\"cell\", \"variable_definition\":\"The total number of Effector T cells present that have exited the lymph nodes\"}"
"{\"compartment_location\":\"Blood-Lymph\", \"variable_name\":\"Effector_T_TB\", \"units\":\"cell\", \"variable_definition\":\"Effector T cells that have been generated from all the lymph nodes considered that are in the process of migrating into the blood\"}"
"{\"compartment_location\":\"Lungs\", \"variable_name\":\"EffT_f_LungsVasc\", \"units\":\"cell\", \"variable_definition\":\"Free effector T cells in the Lung vasculature\"}"
"{\"compartment_location\":\"Lungs\", \"variable_name\":\"EffT_r_LungsVasc\", \"units\":\"cell\", \"variable_definition\":\"Bound effector T cells in the Lung vasculature\"}"
"{\"compartment_location\":\"Lungs\", \"variable_name\":\"EffT_AR_LungsVasc\", \"units\":\"cell\", \"variable_definition\":\"Arrested effector T cells in the Lung vasculature\"}"
"{\"compartment_location\":\"Lungs\", \"variable_name\":\"EffT_LungsEx\", \"units\":\"cell\", \"variable_definition\":\"Effector T cells in the Lung interstitium\"}"
"{\"compartment_location\":\"Lungs\", \"variable_name\":\"Lung_Free_Sites\", \"units\":\"cell\", \"variable_definition\":\"Available binding sites for cells in the Lung vasculature\"}"
"{\"compartment_location\":\"Liv_Spln_GI\", \"variable_name\":\"EffT_Liver_f_Vasc\", \"units\":\"cell\", \"variable_definition\":\"Free effector T cells in the Liver vasculature\"}"
"{\"compartment_location\":\"Liv_Spln_GI\", \"variable_name\":\"EffT_LiverEx\", \"units\":\"cell\", \"variable_definition\":\"Effector T cells in the Liver interstitium\"}"
"{\"compartment_location\":\"Liv_Spln_GI\", \"variable_name\":\"EffT_Liver_b_Vasc\", \"units\":\"cell\", \"variable_definition\":\"Bound effector T cells in the Liver vasculature\"}"
"{\"compartment_location\":\"Liv_Spln_GI\", \"variable_name\":\"EffT_Liver_AR_Vasc\", \"units\":\"cell\", \"variable_definition\":\"Arrested effector T cells in the Liver vasculature\"}"
"{\"compartment_location\":\"Liv_Spln_GI\", \"variable_name\":\"Liver_Free_Sites\", \"units\":\"cell\", \"variable_definition\":\"Available binding sites for cells in the Liver vasculature\"}"
"{\"compartment_location\":\"Liv_Spln_GI\", \"variable_name\":\"EffT_Spleen_f_Vasc\", \"units\":\"cell\", \"variable_definition\":\"Free effector T cells in the Spleen vasculature\"}"
"{\"compartment_location\":\"Liv_Spln_GI\", \"variable_name\":\"EffT_GI_f_Vasc\", \"units\":\"cell\", \"variable_definition\":\"Free effector T cells in the GI vasculature\"}"
"{\"compartment_location\":\"Liv_Spln_GI\", \"variable_name\":\"EffT_SpleenEx\", \"units\":\"cell\", \"variable_definition\":\"Effector T cells in the Spleen interstitium\"}"
"{\"compartment_location\":\"Liv_Spln_GI\", \"variable_name\":\"EffT_Spleen_b_Vasc\", \"units\":\"cell\", \"variable_definition\":\"Bound effector T cells in the Spleen vasculature\"}"
"{\"compartment_location\":\"Liv_Spln_GI\", \"variable_name\":\"EffT_Spleen_AR_Vasc\", \"units\":\"cell\", \"variable_definition\":\"Arrested effector T cells in the Spleen vasculature\"}"
"{\"compartment_location\":\"Liv_Spln_GI\", \"variable_name\":\"Spleen_Free_Sites\", \"units\":\"cell\", \"variable_definition\":\"Available binding sites for cells in the Spleen vasculature\"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"Naive_T\", \"units\":\"cell\", \"variable_definition\":\"Na\u00efve T cells that undergo the first phase of priming in the Lymph Nodes\"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"Primed_Naive_T\", \"units\":\"cell\", \"variable_definition\":\"Primed Naive T cells that undergo the second phase of priming in the Lymph Nodes\"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"PNT_Int_CD28\", \"units\":\"mole\", \"variable_definition\":\"CD28 expressed by interacting Primed Naive T cells engaged in the second priming phase\"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"mAPC\", \"units\":\"cell\", \"variable_definition\":\"Total number of mature antigen presenting cells (mAPCs) in the lymph node compartment\"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"Effector_T\", \"units\":\"cell\", \"variable_definition\":\"Effector T cells that are generate in the lymph node compartment (considering one lymph node)\"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"CTLA4_mab\", \"units\":\"mole\", \"variable_definition\":\"Anti-CTLA-4 antibody in the lymph node \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"Naive_T0\", \"units\":\"cell\", \"variable_definition\":\"Naive T cells that can undergo priming in the lymph node \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"Prolif_Naive_T\", \"units\":\"cell\", \"variable_definition\":\"Proliferating Naive T cells that have undergone the second phase of priming in the lymph node \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"Anergic_Naive_T\", \"units\":\"cell\", \"variable_definition\":\"Primed Naive T cells that do not undergo proliferation following the second phase of priming and are deemed to be anergic T cells in the lymph node \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"PD1_mabLN_ugml\", \"units\":\"\u00b5g/ml\", \"variable_definition\":\"Concentration of anti-PD-1 antibody in the lymph node \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"CTLA4_mab_ugml\", \"units\":\"\u00b5g/ml\", \"variable_definition\":\"Concentration of anti-CTLA-4 antibody in the lymph node \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"PDL1_mabLN_ugml\", \"units\":\"\u00b5g/ml\", \"variable_definition\":\"Concentration of anti-PD-L1 antibody in the lymph node \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"EffT_LN_ExRec\", \"units\":\"cell\", \"variable_definition\":\"Effector T cells in the lymph node interstitium \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"EffT_LN_f_Vasc\", \"units\":\"cell\", \"variable_definition\":\"Free effector T cells in the lymph node vasculature \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"mAPC1\", \"units\":\"cell\", \"variable_definition\":\"mAPCs in lymph node interacting with T regulatory cells \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"Naive_T2\", \"units\":\"cell\", \"variable_definition\":\"Na\u00efve T cells in the lymph node interacting with T regulatory cells \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"Primed_Naive_T2\", \"units\":\"cell\", \"variable_definition\":\"Primed na\u00efve T cells in the lymph node interacting with T regulatory cells \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"mAPC_cells_per_ml\", \"units\":\"cell/ml\", \"variable_definition\":\"Calculation of mAPC in the lymph node \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"PD1_mab\", \"units\":\"mole\", \"variable_definition\":\"Anti-PD-1 antibody in the lymph node \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"PDL1_mab\", \"units\":\"mole\", \"variable_definition\":\"Anti-PD-L1 antibody in the lymph node \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"Naive_T1\", \"units\":\"cell\", \"variable_definition\":\"Naive T cells engaged in the first priming phase in the lymph node \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"Primed_Naive_T1\", \"units\":\"cell\", \"variable_definition\":\"Primed Naive T cells engaged in the second priming phase in the lymph node \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"mAPC_Total_Calc_Pr\", \"units\":\"cell\", \"variable_definition\":\"mAPCs in the lymph node that are not engaged in priming \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"Total_T_CD8-CD4\", \"units\":\"cell\", \"variable_definition\":\"Total number of all T cells in the lymph node \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"PNT1_Int\", \"units\":\"cell\", \"variable_definition\":\"Primed Naive T cells engaged in the second priming phase in the lymph node that are accounting for the expression of immune checkpoints \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"PNT_CTLA4\", \"units\":\"mole\", \"variable_definition\":\"CTLA-4 expressed by interacting Primed Naive T cells engaged in the second priming phase \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"mAPC_Int_P1\", \"units\":\"cell\", \"variable_definition\":\"mAPCs interacting with Naive T cells in the first phase of priming \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"mAPC_Int_P2\", \"units\":\"cell\", \"variable_definition\":\"mAPCs interacting with Primed Naive T cells in the second phase of priming \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"mAPC_Int_P2_CD80\", \"units\":\"mole\", \"variable_definition\":\"CD80 receptors expressed by mAPCs that are involved in the second priming phase interactions \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"mAPC_Int_P2_CD86\", \"units\":\"mole\", \"variable_definition\":\"CD86 receptors expressed by mAPCs that are involved in the second priming phase interactions \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"POS_Sig_PNT_CD80\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between CD28 expressed on Primed Naive T cells and CD80 expressed on mAPCs during the second phase of priming \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"POS_Sig_PNT_CD86\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between CD28 expressed on Primed Naive T cells and CD86 expressed on mAPCs during the second phase of priming \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"NEG_Sig_PNT_CD80\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between CTLA-4 expressed on Primed Naive T cells and CD80 expressed on mAPCs during the second phase of priming \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"NEG_Sig_PNT_CD86\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between CTLA-4 expressed on Primed Naive T cells and CD80 expressed on mAPCs during the second phase of priming \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"CTLA4_mAb_CTLA4\", \"units\":\"mole\", \"variable_definition\":\"Heterogeneous receptor-antibody interactions at the immunological synapse between CTLA-4 expressed on Primed Naive T cells during the second priming phase and Anti-CTLA-4 mAb delivered to the lymph node by way of IV injection into the blood \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"mAPC_Int_P2_PDL1\", \"units\":\"mole\", \"variable_definition\":\"PD-L1 receptors expressed by mAPCs that are involved in the second priming phase interactions \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"mAPC_Int_P2_PDL2\", \"units\":\"mole\", \"variable_definition\":\"PD-L2 receptors expressed by mAPCs that are involved in the second priming phase interactions \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"mAPC_Int_P2_PD1\", \"units\":\"mole\", \"variable_definition\":\"PD-1 receptors expressed by mAPCs that are involved in the second priming phase interactions \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"PNT_Int_CD80\", \"units\":\"mole\", \"variable_definition\":\"CD80 expressed by interacting Primed Naive T cells engaged in the second priming phase \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"PNT_Int_PD1\", \"units\":\"mole\", \"variable_definition\":\"PD-1 expressed by interacting Primed Naive T cells engaged in the second priming phase \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"PNT_Int_PDL1\", \"units\":\"mole\", \"variable_definition\":\"PD-L1 expressed by interacting Primed Naive T cells engaged in the second priming phase \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"PNT_CD80-PDL1\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between CD80 expressed on Primed Naive T cells and PD-L1 expressed on mAPCs during the second phase of priming \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"PNT_PD1-PDL2\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-1 expressed on Primed Naive T cells and PD-L2 expressed on mAPCs during the second phase of priming \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"PNT_PD1-PDL1\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-1 expressed on Primed Naive T cells and PD-L1 expressed on mAPCs during the second phase of priming \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"PNT_PDL1-CD80\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-L1 expressed on Primed Naive T cells and CD80 expressed on mAPCs during the second phase of priming \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"PNT_PDL1-PD1\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-L1 expressed on Primed Naive T cells and PD-1 expressed on mAPCs during the second phase of priming \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"PDL1mAb-PNT_PDL1\", \"units\":\"mole\", \"variable_definition\":\"Heterogenous receptor-antibody interactions at the immunological synapse between PD-L1 expressed on Primed Naive T cells during the second priming phase and Anti-PD-L1 mAb delivered to the lymph node by way of IV injection into the blood \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"PDL1mAb-mAPC_PDL1\", \"units\":\"mole\", \"variable_definition\":\"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-L1 expressed on mAPCs during the second priming phase and Anti-PD-L1 mAb delivered to the lymph node by way of IV injection into the blood \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"PD1mAb_mAPC_PD1\", \"units\":\"mole\", \"variable_definition\":\"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-1 expressed on mAPCs during the second priming phase and Anti-PD-1 mAb delivered to the lymph node by way of IV injection into the blood \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"PD1mAb_PNT_PD1\", \"units\":\"mole\", \"variable_definition\":\"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-1 expressed on Primed Naive T cells during the second priming phase and Anti-PD-1 mAb delivered to the lymph node by way of IV injection into the blood \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"mAPC_PD1\", \"units\":\"mole\", \"variable_definition\":\"Total PD-1 expression by all mAPCs in the lymph node \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"mAPC_PDL2\", \"units\":\"mole\", \"variable_definition\":\"Total PD-L2 expression by all mAPCs in the lymph node \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"mAPC_PDL1\", \"units\":\"mole\", \"variable_definition\":\"Total PD-L1 expression by all mAPCs in the lymph node \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"mAPC_CD86\", \"units\":\"mole\", \"variable_definition\":\"Total CD86 expression by all mAPCs in the lymph node \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"mAPC_CD80\", \"units\":\"mole\", \"variable_definition\":\"Total CD80 expression by all mAPCs in the lymph node \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"TregLN-NT\", \"units\":\"cell\", \"variable_definition\":\"T Regulatory cells in the lymph node that have engaged in interacting with Na\u00efve T cells \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"TregLN-PNT\", \"units\":\"cell\", \"variable_definition\":\"T Regulatory cells in the lymph node that have engaged in interacting with Primed Na\u00efve T cells \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"TregLN_mAPC\", \"units\":\"cell\", \"variable_definition\":\"T Regulatory cells in the lymph node that have engaged in interacting with mAPCs \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"TregLN\", \"units\":\"cell\", \"variable_definition\":\"Total number of T Regulatory cells that able to engage with other cell types in the lymph node \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"Tr-mAPC_CTLA4\", \"units\":\"mole\", \"variable_definition\":\"CTLA-4 receptors expressed by T Regulatory cells in the lymph node \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"Tr-PNT_PD1\", \"units\":\"mole\", \"variable_definition\":\"PD-1 receptors expressed by T Regulatory cells in the lymph node \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"Tr-PNT_PDL1\", \"units\":\"mole\", \"variable_definition\":\"PD-L1 receptors expressed by T Regulatory cells in the lymph node \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"PNT-Tr_PDL1\", \"units\":\"mole\", \"variable_definition\":\"PD-L1 receptors expressed by Primed Na\u00efve T cells in the lymph node during engagement with T Regulatory cells \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"PNT-Tr_PD1\", \"units\":\"mole\", \"variable_definition\":\"PD-1 receptors expressed by Primed Na\u00efve T cells in the lymph node during engagement with T Regulatory cells \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"PNT-Tr_CD80\", \"units\":\"mole\", \"variable_definition\":\"CD80 receptors expressed by Primed Na\u00efve T cells in the lymph node during engagement with T Regulatory cells \"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"TrALN_CT_CD80\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between CTLA-4 expressed on T Regulatory cells and CD80 expressed on mAPCs in the lymph node\"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"TrALN_CT_CD86\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between CTLA-4 expressed on T Regulatory cells and CD86 expressed on mAPCs in the lymph node\"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"TrPNT_PD1-L1\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-1 expressed on T Regulatory cells and PD-L1 expressed on Primed Na\u00efve T cells in the lymph node\"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"TrPNT_PDL1-PD1\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-L1 expressed on T Regulatory cells and PD-1 expressed on Primed Na\u00efve T cells in the lymph node\"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"TrPNT_PDL1-CD80\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-L1 expressed on T Regulatory cells and CD80 expressed on Primed Na\u00efve T cells in the lymph node\"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"TrALN_CT_aCT\", \"units\":\"mole\", \"variable_definition\":\"Heterogeneous receptor-antibody interactions at the immunological synapse between CTLA-4 expressed on T Regulatory cells and Anti-CTLA-4 mAb delivered to the lymph node by way of IV injection into the blood\"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"TrPNT_PD1_aPD1\", \"units\":\"mole\", \"variable_definition\":\"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-1 expressed on T Regulatory cells and Anti-PD-1 mAb delivered to the lymph node by way of IV injection into the blood\"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"PNTTr_PDL1_aPDL1\", \"units\":\"mole\", \"variable_definition\":\"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-L1 expressed on Primed Na\u00efve T cells and Anti-PD-L1 mAb delivered to the lymph node by way of IV injection into the blood\"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"TrPNT_PDL1_aPDL1\", \"units\":\"mole\", \"variable_definition\":\"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-L1 expressed on T Regulatory cells and Anti-PD-L1 mAb delivered to the lymph node by way of IV injection into the blood\"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"PNTTr_PD1_aPD1\", \"units\":\"mole\", \"variable_definition\":\"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-1 expressed on Primed Na\u00efve T cells and Anti-PD-1 mAb delivered to the lymph node by way of IV injection into the blood\"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"Tr-mAPC_CD80\", \"units\":\"mole\", \"variable_definition\":\"CD80 receptors expressed by mACPs that are interacting with T Regulatory cells in the lymph node\"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"Tr-mAPC_CD86\", \"units\":\"mole\", \"variable_definition\":\"CD86 receptors expressed by mACPs that are interacting with T Regulatory cells in the lymph node\"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"TregLN_mAPC1\", \"units\":\"cell\", \"variable_definition\":\"T Regulatory cells in the lymph node that have engaged in interacting with mAPCs in the lymph node that are accounting for the expression of immune checkpoints\"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"TregLN-PNT1\", \"units\":\"cell\", \"variable_definition\":\"T Regulatory cells in the lymph node that have engaged in interacting with Primed Na\u00efve T cells in the lymph node that are accounting for the expression of immune checkpoints\"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"C_DebrisLN\", \"units\":\"cell\", \"variable_definition\":\"Cancer debris that has been transported to the lymph node\"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"APCLN\", \"units\":\"cell\", \"variable_definition\":\"Resident antigen presenting cells in the lymph node that have not yet phagocytosed tumor debris\"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"TrLN_CTLA4\", \"units\":\"mole\", \"variable_definition\":\"CTLA-4 expressed on the surface of non-interacting T Regulatory cells\"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"TrLN_CT_aCT\", \"units\":\"mole\", \"variable_definition\":\"Receptor-antibody interactions between CTLA-4 expressed on T Regulatory cells and Anti-CTLA-4 mAb delivered to the lymph node by way of IV injection into the blood\"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"PNT1_Int1\", \"units\":\"cell\", \"variable_definition\":\"Naive T cells undergoing the first priming phase in the lymph node that are accounting for the expression of immune checkpoints\"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"NT1_Int1\", \"units\":\"cell\", \"variable_definition\":\"Naive T cells undergoing the first priming phase in the lymph node that are accounting for the expression of CD28\"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"NT_Int_CD28\", \"units\":\"mole\", \"variable_definition\":\"CD28 expressed to the immunological synapse of Naive T cells that are undergoing the first phase of priming\"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"mAPC_Int_P1_CD86\", \"units\":\"mole\", \"variable_definition\":\"CD86 receptors expressed by mAPCs that are involved in the first priming phase interactions with Na\u00efve T cells\"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"mAPC_Int_P1_CD80\", \"units\":\"mole\", \"variable_definition\":\"CD80 receptors expressed by mAPCs that are involved in the first priming phase interactions with Na\u00efve T cells\"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"POS_Sig_NT_CD86\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between CD28 expressed on Naive T cells and CD86 expressed on mAPCs during the first phase of priming\"}"
"{\"compartment_location\":\"Lymph_Node\", \"variable_name\":\"POS_Sig_NT_CD80\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between CD28 expressed on Naive T cells and CD86 expressed on mAPCs during the first phase of priming\"}"
"{\"compartment_location\":\"Peripheral\", \"variable_name\":\"CTLA4_leaky_ugml\", \"units\":\"\u00b5g/ml\", \"variable_definition\":\"Concentration of anti-CTLA-4 in leaky tissue\"}"
"{\"compartment_location\":\"Peripheral\", \"variable_name\":\"CTLA4_mabP_leaky\", \"units\":\"mole\", \"variable_definition\":\"Amount of anti-CTLA-4 in leaky tissue\"}"
"{\"compartment_location\":\"Peripheral\", \"variable_name\":\"CTLA4_mabP_tight\", \"units\":\"mole\", \"variable_definition\":\"Amount of anti-CTLA-4 in tight tissue\"}"
"{\"compartment_location\":\"Peripheral\", \"variable_name\":\"CTLA4_tight_ugml\", \"units\":\"\u00b5g/ml\", \"variable_definition\":\"Concentration of anti-CTLA-4 in tight tissue\"}"
"{\"compartment_location\":\"Peripheral\", \"variable_name\":\"EffT_P_f_Vasc\", \"units\":\"cell\", \"variable_definition\":\"Free effector T cells in the peripheral vasculature\"}"
"{\"compartment_location\":\"Peripheral\", \"variable_name\":\"PD1_leaky_ugml\", \"units\":\"\u00b5g/ml\", \"variable_definition\":\"Concentration of anti-PD-1 in leaky tissue\"}"
"{\"compartment_location\":\"Peripheral\", \"variable_name\":\"PD1_mabP_leaky\", \"units\":\"mole\", \"variable_definition\":\"Amount of anti-PD-1 in leaky tissue\"}"
"{\"compartment_location\":\"Peripheral\", \"variable_name\":\"PD1_mabP_tight\", \"units\":\"mole\", \"variable_definition\":\"Amount of anti-PD-1 in tight tissue\"}"
"{\"compartment_location\":\"Peripheral\", \"variable_name\":\"PD1_tight_ugml\", \"units\":\"\u00b5g/ml\", \"variable_definition\":\"Concentration of anti-PD-1 in tight tissue\"}"
"{\"compartment_location\":\"Peripheral\", \"variable_name\":\"PDL1_leaky_ugml\", \"units\":\"\u00b5g/ml\", \"variable_definition\":\"Concentration of anti-PD-L1 in leaky tissue\"}"
"{\"compartment_location\":\"Peripheral\", \"variable_name\":\"PDL1_mabP_leaky\", \"units\":\"mole\", \"variable_definition\":\"Amount of anti-PD-L1 in leaky tissue\"}"
"{\"compartment_location\":\"Peripheral\", \"variable_name\":\"PDL1_mabP_tight\", \"units\":\"mole\", \"variable_definition\":\"Amount of anti-PD-L1 in tight tissue\"}"
"{\"compartment_location\":\"Peripheral\", \"variable_name\":\"PDL1_tight_ugml\", \"units\":\"\u00b5g/ml\", \"variable_definition\":\"Concentration of anti-PD-L1 in tight tissue\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"PD1_mabt\", \"units\":\"mole\", \"variable_definition\":\"Anti-PD-1 antibody in the tumor compartment\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"PDL1_mabt\", \"units\":\"mole\", \"variable_definition\":\"Anti-PD-L1 antibody in the tumor compartment\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"CTLA4_mabt\", \"units\":\"mole\", \"variable_definition\":\"Anti-CTLA-4 antibody in the tumor compartment\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"Effector_TT\", \"units\":\"cell\", \"variable_definition\":\"Effector T cells in the tumor microenvironment\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"Cancer\", \"units\":\"cell\", \"variable_definition\":\"Cancer cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"Effector_TT_C_Eng\", \"units\":\"cell\", \"variable_definition\":\"Effector T cells that can engage with cancer cells in the tumor microenvironment\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"TC1\", \"units\":\"cell\", \"variable_definition\":\"Cancer cells that are engaged with Effector T cells in the tumor microenvironment\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T_Recover_Can_Dead\", \"units\":\"cell\", \"variable_definition\":\"Effector T cells that have disengaged from the cancer cells in the tumor and are in delay state prior to being able to bind other cancer cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C_DebrisT\", \"units\":\"cell\", \"variable_definition\":\"Cancer debris in the tumor that has resulted from cancer death\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"TC2\", \"units\":\"cell\", \"variable_definition\":\"Effector T cells that are engaged with cancer cells in the tumor microenvironment\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"Monocytes\", \"units\":\"cell\", \"variable_definition\":\"Monocytes that migrate into the tumor and differentiate into APCs\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"APC_T\", \"units\":\"cell\", \"variable_definition\":\"Antigen Presenting Cells (APCs) in the tumor that can phagocytose tumor debris (tumor antigens) and become mature APCs\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"mAPC_T\", \"units\":\"cell\", \"variable_definition\":\"Mature Antigen Presenting Cells (mAPCs) in the tumor that resulted from APCs that have phagocytosed tumor debris\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"PD1_mabt\", \"units\":\"mole\", \"variable_definition\":\"Moles of anti-PD-1 antibody in the tumor interstitium\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"PD1_mabT_ugml\", \"units\":\"\u00b5g/ml\", \"variable_definition\":\"Concentration of anti-PD-1 antibody in the tumor interstitium\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"CTLA4_mabt_ugml\", \"units\":\"\u00b5g/ml\", \"variable_definition\":\"Concentration of anti-CTLA-4 antibody in the tumor interstitium\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"PDL1_mabT_ugml\", \"units\":\"\u00b5g/ml\", \"variable_definition\":\"Concentration of anti-PD-L1 antibody in the tumor interstitium\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"EffT_f_Vasc\", \"units\":\"cell\", \"variable_definition\":\"Free effector T cells in the tumor vasculature\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"Tmr_Free_Sites\", \"units\":\"cell\", \"variable_definition\":\"Available binding sites for cells in the tumor vasculature\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"EffT_b_Vasc\", \"units\":\"cell\", \"variable_definition\":\"Bound effector T cells in the tumor vasculature\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"EffT_AR_Vasc\", \"units\":\"cell\", \"variable_definition\":\"Arrested effector T cells in the tumor vasculature\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"Cancer1\", \"units\":\"cell\", \"variable_definition\":\"Cancer cells that can engage with Effector T cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T{PD1}{CD80}-{PDL1}C\", \"units\":\"cell\", \"variable_definition\":\"Effector T cells in the tumor that interact with the T3 subgroup of cancer cells expressing PD-L1 only, and other unknown factors\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T{PD1}-{PDL2}C\", \"units\":\"cell\", \"variable_definition\":\"Effector T cells in the tumor that interact with the T4 subgroup of cancer cells expressing PD-L2 only, and other unknown factors\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T{PDL1}-{PD1}C\", \"units\":\"cell\", \"variable_definition\":\"Effector T cells in the tumor that interact with the T2 subgroup of cancer cells expressing PD-1 only, and other unknown factors\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T{PDL1}-{CD80}C\", \"units\":\"cell\", \"variable_definition\":\"Effector T cells in the tumor that interact with the T5 subgroup of cancer cells expressing CD80 only, and other unknown factors\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T{PD1}{L1}{80}-{PD1}{L1}C\", \"units\":\"cell\", \"variable_definition\":\"Effector T cells in the tumor that interact with the T6 subgroup of cancer cells expressing PD-1 and PD-L1 only, and other unknown factors\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T{PD1}{80}-{PDL1}{PDL2}C\", \"units\":\"cell\", \"variable_definition\":\"Effector T cells in the tumor that interact with the T8 subgroup of cancer cells expressing PD-L1 and PD-L2 only, and other unknown factors\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T{PD1}{L1}-{PD1}{L2}C\", \"units\":\"cell\", \"variable_definition\":\"Effector T cells in the tumor that interact with the T7 subgroup of cancer cells expressing PD-1 and PD-L2 only, and other unknown factors\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T{PD1}{L1}{80}-{PD1}{L1}{L2}C\", \"units\":\"cell\", \"variable_definition\":\"Effector T cells in the tumor that interact with the T10 subgroup of cancer cells expressing PD-1, PD-L1 and PD-L2 only, and other unknown factors\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T{PDL1}-{CD80}{PD1}C\", \"units\":\"cell\", \"variable_definition\":\"Effector T cells in the tumor that interact with the T9 subgroup of cancer cells expressing CD80 and PD-1 only, and other unknown factors\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T{PD1}{L1}-{PDL1}{80}C\", \"units\":\"cell\", \"variable_definition\":\"Effector T cells in the tumor that interact with the T11 subgroup of cancer cells expressing PD-L1 and CD80 only, and other unknown factors\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T{PD1}{L1}-{PDL2}{80}C\", \"units\":\"cell\", \"variable_definition\":\"Effector T cells in the tumor that interact with the T12 subgroup of cancer cells expressing PD-L2 and CD80 only, and other unknown factors\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T{PD1}{L1}-{PDL1}{80}{L2}C\", \"units\":\"cell\", \"variable_definition\":\"Effector T cells in the tumor that interact with the T13 subgroup of cancer cells expressing PD-L1, CD80 and PD- L2 only, and other unknown factors\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T{PD1}{L1}{80}-{PD1}{80}{L1}C\", \"units\":\"cell\", \"variable_definition\":\"Effector T cells in the tumor that interact with the T14 subgroup of cancer cells expressing PD-1, CD80 and PD-L1 only, and other unknown factors\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T{PD1}{L1}-{PD1}{80}{PDL2}C\", \"units\":\"cell\", \"variable_definition\":\"Effector T cells in the tumor that interact with the T15 subgroup of cancer cells expressing PD-1, CD80 and PD- L2 only, and other unknown factors\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T{PD1}{L1}{80}- {PD1}{80}{L1}{L2}C\", \"units\":\"cell\", \"variable_definition\":\"Effector T cells in the tumor that interact with the T16 subgroup of cancer cells expressing PD-1, CD80, PD-L1 and PD-L2 only, and other unknown factors\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T2=PDL1\", \"units\":\"mole\", \"variable_definition\":\"PD-L1 expressed by Effector T cells that interact with T2 subgroup of cancer cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T3a=PD1\", \"units\":\"mole\", \"variable_definition\":\"PD-1 expressed by Effector T cells that interact with T3 subgroup of cancer cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T4=PD1\", \"units\":\"mole\", \"variable_definition\":\"PD-1 expressed by Effector T cells that interact with T4 subgroup of cancer cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T5=PDL1\", \"units\":\"mole\", \"variable_definition\":\"PD-L1 expressed by Effector T cells that interact with T5 subgroup of cancer cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T3b=CD80\", \"units\":\"mole\", \"variable_definition\":\"CD80 expressed by Effector T cells that interact with T3 subgroup of cancer cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T7a=PDL1\", \"units\":\"mole\", \"variable_definition\":\"PD-L1 expressed by Effector T cells that interact with T7 subgroup of cancer cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T10b=PD1\", \"units\":\"mole\", \"variable_definition\":\"PD-1 expressed by Effector T cells that interact with T10 subgroup of cancer cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T7b=PD1\", \"units\":\"mole\", \"variable_definition\":\"PD-1 expressed by Effector T cells that interact with T7 subgroup of cancer cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T6a=PDL1\", \"units\":\"mole\", \"variable_definition\":\"PD-L1 expressed by Effector T cells that interact with T6 subgroup of cancer cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T6c=CD80\", \"units\":\"mole\", \"variable_definition\":\"CD80 expressed by Effector T cells that interact with T6 subgroup of cancer cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T6b=PD1\", \"units\":\"mole\", \"variable_definition\":\"PD-1 expressed by Effector T cells that interact with T6 subgroup of cancer cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T11a=PDL1\", \"units\":\"mole\", \"variable_definition\":\"PD-L1 expressed by Effector T cells that interact with T11 subgroup of cancer cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T11b=PD1\", \"units\":\"mole\", \"variable_definition\":\"PD-1 expressed by Effector T cells that interact with T11 subgroup of cancer cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T10c=CD80\", \"units\":\"mole\", \"variable_definition\":\"CD80 expressed by Effector T cells that interact with T10 subgroup of cancer cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T12b=PD1\", \"units\":\"mole\", \"variable_definition\":\"PD-1 expressed by Effector T cells that interact with T12 subgroup of cancer cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T13a=PDL1\", \"units\":\"mole\", \"variable_definition\":\"PD-L1 expressed by Effector T cells that interact with T13 subgroup of cancer cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T12a=PDL1\", \"units\":\"mole\", \"variable_definition\":\"PD-L1 expressed by Effector T cells that interact with T12 subgroup of cancer cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T14c=CD80\", \"units\":\"mole\", \"variable_definition\":\"CD80 expressed by Effector T cells that interact with T14 subgroup of cancer cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T15b=PD1\", \"units\":\"mole\", \"variable_definition\":\"PD-1 expressed by Effector T cells that interact with T15 subgroup of cancer cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T15a=PDL1\", \"units\":\"mole\", \"variable_definition\":\"PD-L1 expressed by Effector T cells that interact with T15 subgroup of cancer cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T13b=PD1\", \"units\":\"mole\", \"variable_definition\":\"PD-1 expressed by Effector T cells that interact with T13 subgroup of cancer cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T14b=PD1\", \"units\":\"mole\", \"variable_definition\":\"PD-1 expressed by Effector T cells that interact with T14 subgroup of cancer cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T14a=PDL1\", \"units\":\"mole\", \"variable_definition\":\"PD-L1 expressed by Effector T cells that interact with T14 subgroup of cancer cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T16b=PD1\", \"units\":\"mole\", \"variable_definition\":\"PD-1 expressed by Effector T cells that interact with T16 subgroup of cancer cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T16c=CD80\", \"units\":\"mole\", \"variable_definition\":\"CD80 expressed by Effector T cells that interact with T16 subgroup of cancer cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T16a=PDL1\", \"units\":\"mole\", \"variable_definition\":\"PD-L1 expressed by Effector T cells that interact with T16 subgroup of cancer cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T8a=PD1\", \"units\":\"mole\", \"variable_definition\":\"PD-1 expressed by Effector T cells that interact with T8 subgroup of cancer cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T8b=CD80\", \"units\":\"mole\", \"variable_definition\":\"CD80 expressed by Effector T cells that interact with T8 subgroup of cancer cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T9=PDL1\", \"units\":\"mole\", \"variable_definition\":\"PD-L1 expressed by Effector T cells that interact with T9 subgroup of cancer cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T10a=PDL1\", \"units\":\"mole\", \"variable_definition\":\"PD-L1 expressed by Effector T cells that interact with T10 subgroup of cancer cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C10a=PD1\", \"units\":\"mole\", \"variable_definition\":\"PD-1 expressed by the T10 subtype of cancer cells that interact with Effector T cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C9b=CD80\", \"units\":\"mole\", \"variable_definition\":\"CD80 expressed by the T9 subtype of cancer cells that interact with Effector T cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C9a=PD1\", \"units\":\"mole\", \"variable_definition\":\"PD-1 expressed by the T9 subtype of cancer cells that interact with Effector T cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C8b=PDL2\", \"units\":\"mole\", \"variable_definition\":\"PD-L2 expressed by the T8 subtype of cancer cells that interact with Effector T cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C16a=PD1\", \"units\":\"mole\", \"variable_definition\":\"PD-1 expressed by the T16 subtype of cancer cells that interact with Effector T cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C16c=PDL2\", \"units\":\"mole\", \"variable_definition\":\"PD-L2 expressed by the T16 subtype of cancer cells that interact with Effector T cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C16b=PDL1\", \"units\":\"mole\", \"variable_definition\":\"PD-L1 expressed by the T16 subtype of cancer cells that interact with Effector T cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C14a=PD1\", \"units\":\"mole\", \"variable_definition\":\"PD-1 expressed by the T14 subtype of cancer cells that interact with Effector T cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C14b=PDL1\", \"units\":\"mole\", \"variable_definition\":\"PD-L1 expressed by the T14 subtype of cancer cells that interact with Effector T cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C13b=PDL2\", \"units\":\"mole\", \"variable_definition\":\"PD-L2 expressed by the T13 subtype of cancer cells that interact with Effector T cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C15a=PD1\", \"units\":\"mole\", \"variable_definition\":\"PD-1 expressed by the T15 subtype of cancer cells that interact with Effector T cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C15b=PDL2\", \"units\":\"mole\", \"variable_definition\":\"PD-L2 expressed by the T15 subtype of cancer cells that interact with Effector T cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C14c=CD80\", \"units\":\"mole\", \"variable_definition\":\"CD80 expressed by the T14 subtype of cancer cells that interact with Effector T cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C12a=PDL2\", \"units\":\"mole\", \"variable_definition\":\"PD-L2 expressed by the T12 subtype of cancer cells that interact with Effector T cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C13a=PDL1\", \"units\":\"mole\", \"variable_definition\":\"PD-L1 expressed by the T13 subtype of cancer cells that interact with Effector T cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C12b=CD80\", \"units\":\"mole\", \"variable_definition\":\"CD80 expressed by the T12 subtype of cancer cells that interact with Effector T cells in the tumor \"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C10c=PDL2\", \"units\":\"mole\", \"variable_definition\":\"PD-L2 expressed by the T10 subtype of cancer cells that interact with Effector T cells in the tumor \"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C11b=CD80\", \"units\":\"mole\", \"variable_definition\":\"CD80 expressed by the T11 subtype of cancer cells that interact with Effector T cells in the tumor \"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C11a=PDL1\", \"units\":\"mole\", \"variable_definition\":\"PD-L1 expressed by the T11 subtype of cancer cells that interact with Effector T cells in the tumor \"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C6b=PDL1\", \"units\":\"mole\", \"variable_definition\":\"PD-L1 expressed by the T6 subtype of cancer cells that interact with Effector T cells in the tumor \"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C7a=PD1\", \"units\":\"mole\", \"variable_definition\":\"PD-1 expressed by the T7 subtype of cancer cells that interact with Effector T cells in the tumor \"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C6a=PD1\", \"units\":\"mole\", \"variable_definition\":\"PD-1 expressed by the T6 subtype of cancer cells that interact with Effector T cells in the tumor \"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C8a=PDL1\", \"units\":\"mole\", \"variable_definition\":\"PD-L1 expressed by the T8 subtype of cancer cells that interact with Effector T cells in the tumor \"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C10b=PDL1\", \"units\":\"mole\", \"variable_definition\":\"PD-L1 expressed by the T10 subtype of cancer cells that interact with Effector T cells in the tumor \"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C7b=PDL2\", \"units\":\"mole\", \"variable_definition\":\"PD-L2 expressed by the T7 subtype of cancer cells that interact with Effector T cells in the tumor \"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C5=CD80\", \"units\":\"mole\", \"variable_definition\":\"CD80 expressed by the T5 subtype of cancer cells that interact with Effector T cells in the tumor \"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C4=PDL2\", \"units\":\"mole\", \"variable_definition\":\"PD-L2 expressed by the T4 subtype of cancer cells that interact with Effector T cells in the tumor \"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C3=PDL1\", \"units\":\"mole\", \"variable_definition\":\"PD-L1 expressed by the T3 subtype of cancer cells that interact with Effector T cells in the tumor \"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C2=PD1\", \"units\":\"mole\", \"variable_definition\":\"PD-1 expressed by the T2 subtype of cancer cells that interact with Effector T cells in the tumor \"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C{PD1}\", \"units\":\"cell\", \"variable_definition\":\"T2 subgroup of cancer cells expressing PD-1 only, and other unknown factors \"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C{PDL1}\", \"units\":\"cell\", \"variable_definition\":\"T3 subgroup of cancer cells expressing PD-L1 only, and other unknown factors \"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C{PDL2}\", \"units\":\"cell\", \"variable_definition\":\"T4 subgroup of cancer cells expressing PD-L2 only, and other unknown factors \"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C{CD80}\", \"units\":\"cell\", \"variable_definition\":\"T5 subgroup of cancer cells expressing CD80 only, and other unknown factors \"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C{PD1}{PDL1}\", \"units\":\"cell\", \"variable_definition\":\"T6 subgroup of cancer cells expressing PD-1 and PD-L1 only, and other unknown factors \"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C{PD1}{PDL2}\", \"units\":\"cell\", \"variable_definition\":\"T7 subgroup of cancer cells expressing PD-1 and PD-L2 only, and other unknown factors \"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C{PDL1}{PDL2}\", \"units\":\"cell\", \"variable_definition\":\"T8 subgroup of cancer cells expressing PD-L1 and PD-L2 only, and other unknown factors \"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C{PD1}{CD80}\", \"units\":\"cell\", \"variable_definition\":\"T9 subgroup of cancer cells expressing PD-1 and CD80 only, and other unknown factors \"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C{PD1}{PDL1}{PDL2}\", \"units\":\"cell\", \"variable_definition\":\"T10 subgroup of cancer cells expressing PD-1, PD-L1 and PD-L2 only, and other unknown factors \"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C{PDL1}{CD80}\", \"units\":\"cell\", \"variable_definition\":\"T11 subgroup of cancer cells expressing PD-L1 and CD80 only, and other unknown factors \"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C{PDL2}{CD80}\", \"units\":\"cell\", \"variable_definition\":\"T12 subgroup of cancer cells expressing PD-L2 and CD80 only, and other unknown factors \"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C{PDL1}{PDL2}{CD80}\", \"units\":\"cell\", \"variable_definition\":\"T13 subgroup of cancer cells expressing PD-L1, PDL-L2 and CD80 only, and other unknown factors \"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C{PD1}{PDL1}{CD80}\", \"units\":\"cell\", \"variable_definition\":\"T14 subgroup of cancer cells expressing PD-1, PD-L1 and CD80 only, and other unknown factors \"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C{PD1}{PDL2}{CD80}\", \"units\":\"cell\", \"variable_definition\":\"T15 subgroup of cancer cells expressing PD-1, PD-L2 and CD80 only, and other unknown factors \"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C{PD1}{PDL1}{PDL2}{CD80}\", \"units\":\"cell\", \"variable_definition\":\"T16 subgroup of cancer cells expressing PD-1, PD-L1, PD- L2 and CD80 only, and other unknown factors \"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C13c=CD80\", \"units\":\"mole\", \"variable_definition\":\"CD80 expressed by the T13 subtype of cancer cells that interact with Effector T cells in the tumor \"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C15c=CD80\", \"units\":\"mole\", \"variable_definition\":\"CD80 expressed by the T15 subtype of cancer cells that interact with Effector T cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C16d=CD80\", \"units\":\"mole\", \"variable_definition\":\"CD80 expressed by the T16 subtype of cancer cells that interact with Effector T cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T2=PDL1:PD1=C2\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-1 expressed by the T2 subtype of cancer cells and PD-L1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T3a=PD1:PDL1=C3\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-L1 expressed by the T3 subtype of cancer cells and PD-1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T3b=CD80:PDL1=C3\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-L1 expressed by the T3 subtype of cancer cells and CD80 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T4=PD1:PDL2=C4\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-L2 expressed by the T4 subtype of cancer cells and PD-1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T5=PDL1:CD80=C5\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between CD80 expressed by the T5 subtype of cancer cells and PD-L1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T6a=PDL1:PD1=C6a\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-1 expressed by the T6 subtype of cancer cells and PD-L1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T6c=CD80:PDL1=C6b\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-L1 expressed by the T6 subtype of cancer cells and CD80 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T6b=PD1:PDL1=C6b\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-L1 expressed by the T6 subtype of cancer cells and PD-1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T7a=PDL1:PD1=C7a\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-1 expressed by the T7 subtype of cancer cells and PD-L1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T7b=PD1:PDL2=C7b\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-L2 expressed by the T7 subtype of cancer cells and PD-1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T8a=PD1:PDL2=C8b\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-L2 expressed by the T8 subtype of cancer cells and PD-1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T8a=PD1:PDL1=C8a\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-L1 expressed by the T8 subtype of cancer cells and PD-1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T8b=CD80:PDL1=C8a\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-L1 expressed by the T8 subtype of cancer cells and CD80 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T9=PDL1-PD1=C9a\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-1 expressed by the T9 subtype of cancer cells and PD-L1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T9=PDL1-CD80=C9b\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between CD80 expressed by the T9 subtype of cancer cells and PD-L1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T10a=PDL1:PD1=C10a\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-1 expressed by the T10 subtype of cancer cells and PD-L1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T10b=PD1:PDL1=C10b\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-L1 expressed by the T10 subtype of cancer cells and PD-1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T10b=PD1:PDL2=C10c\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-L2 expressed by the T10 subtype of cancer cells and PD-1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T10c=CD80:PDL1=C10b\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-L1 expressed by the T10 subtype of cancer cells and CD80 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T11b=PD1:PDL1=C11a\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-L1 expressed by the T11 subtype of cancer cells and PD-1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T11a=PDL1:CD80=C11b\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between CD80 expressed by the T11 subtype of cancer cells and PD-L1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T12b=PD1:PDL2=C12a\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-L2 expressed by the T12 subtype of cancer cells and PD-1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T12a=PDL1:CD80=C12b\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between CD80 expressed by the T12 subtype of cancer cells and PD-L1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T13b=PD1:PDL1=C13a\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-L1 expressed by the T13 subtype of cancer cells and PD-1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T13a=PDL1:CD80=C13c\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between CD80 expressed by the T13 subtype of cancer cells and PD-L1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T13b=PD1:PDL2=C13b\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-L2 expressed by the T13 subtype of cancer cells and PD-1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T14a=PDL1:PD1=C14a\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-1 expressed by the T14 subtype of cancer cells and PD-L1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T14a=PDL1:CD80=C14c\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between CD80 expressed by the T14 subtype of cancer cells and PD-L1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T14b=PD1:PDL1=C14b\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-L1 expressed by the T14 subtype of cancer cells and PD-1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T14c=CD80:PDL1=C14b\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between CD80 expressed by the T14 subtype of cancer cells and PD-L1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T15a=PDL1:CD80=C15c\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between CD80 expressed by the T15 subtype of cancer cells and PD-L1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T15a=PDL1:PD1=C15a\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-1 expressed by the T15 subtype of cancer cells and PD-L1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T15b=PD1:PDL2=C15b\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-L2 expressed by the T15 subtype of cancer cells and PD-1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T16b=PD1:PDL2=C16c\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-L2 expressed by the T15 subtype of cancer cells and PD-1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T16b=PD1:PDL1=C16b\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-L1 expressed by the T15 subtype of cancer cells and PD-1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T16c=CD80:PDL1=C16b\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-L1 expressed by the T15 subtype of cancer cells and CD80 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T16a=PDL1:PD1=C16a\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-1 expressed by the T15 subtype of cancer cells and PD-L1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T16a=PDL1:CD80=C16d\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between CD80 expressed by the T15 subtype of cancer cells and PD-L1 expressed on Effector T cells\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T2=PDL1:aPDL1\", \"units\":\"mole\", \"variable_definition\":\"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-L1 expressed by Effector T cells that interact with the T2 subtype of cancer cells and Anti-PD-L1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T3a=PD1:aPD1\", \"units\":\"mole\", \"variable_definition\":\"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-1 expressed by Effector T cells that interact with the T3 subtype of cancer cells and Anti-PD-L1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"C3=PDL1:aPDL1\", \"units\":\"mole\", \"variable_definition\":\"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-L1 expressed by the T3 subtype of cancer cells and Anti-PD-L1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"T16a=PDL1:aPDL1\", \"units\":\"mole\", \"variable_definition\":\"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-L1 expressed by Effector T cells that interact with the T16 subtype of cancer cells and Anti-PD-L1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\": \"Tumor\", \"variable_name\": \"C16b=PDL1:aPDL1\", \"units\": \"mole\", \"variable_definition\": \"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-L1 expressed by the T16 subtype of cancer cells and Anti-PD-L1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\": \"Tumor\", \"variable_name\": \"C2=PD1:aPD1\", \"units\": \"mole\", \"variable_definition\": \"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-1 expressed by the T2 subtype of cancer cells and Anti-PD-1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\": \"Tumor\", \"variable_name\": \"T4=PD1:aPD1\", \"units\": \"mole\", \"variable_definition\": \"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-1 expressed by Effector T cells that interact with the T4 subtype of cancer cells and Anti-PD-L1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\": \"Tumor\", \"variable_name\": \"C6a=PD1:aPD1\", \"units\": \"mole\", \"variable_definition\": \"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-1 expressed by the T6 subtype of cancer cells and Anti-PD-1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\": \"Tumor\", \"variable_name\": \"T6b=PD1:aPD1\", \"units\": \"mole\", \"variable_definition\": \"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-1 expressed by Effector T cells that interact with the T6 subtype of cancer cells and Anti-PD-L1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\": \"Tumor\", \"variable_name\": \"C7a=PD1:aPD1\", \"units\": \"mole\", \"variable_definition\": \"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-1 expressed by the T7 subtype of cancer cells and Anti-PD-1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\": \"Tumor\", \"variable_name\": \"T7b=PD1:aPD1\", \"units\": \"mole\", \"variable_definition\": \"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-1 expressed by Effector T cells that interact with the T7 subtype of cancer cells and Anti-PD-L1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\": \"Tumor\", \"variable_name\": \"T8a=PD1:aPD1\", \"units\": \"mole\", \"variable_definition\": \"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-1 expressed by Effector T cells that interact with the T8 subtype of cancer cells and Anti-PD-L1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\": \"Tumor\", \"variable_name\": \"C9a=PD1:aPD1\", \"units\": \"mole\", \"variable_definition\": \"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-1 expressed by the T9 subtype of cancer cells and Anti-PD-1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\": \"Tumor\", \"variable_name\": \"C10a=PD1:aPD1\", \"units\": \"mole\", \"variable_definition\": \"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-1 expressed by the T10 subtype of cancer cells and Anti-PD-1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\": \"Tumor\", \"variable_name\": \"T10b=PD1:aPD1\", \"units\": \"mole\", \"variable_definition\": \"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-1 expressed by Effector T cells that interact with the T10 subtype of cancer cells and Anti-PD-L1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\": \"Tumor\", \"variable_name\": \"T11b=PD1:aPD1\", \"units\": \"mole\", \"variable_definition\": \"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-1 expressed by Effector T cells that interact with the T11 subtype of cancer cells and Anti-PD-L1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\": \"Tumor\", \"variable_name\": \"T13b=PD1:aPD1\", \"units\": \"mole\", \"variable_definition\": \"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-1 expressed by Effector T cells that interact with the T13 subtype of cancer cells and Anti-PD-L1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\": \"Tumor\", \"variable_name\": \"C14a=PD1:aPD1\", \"units\": \"mole\", \"variable_definition\": \"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-1 expressed by the T14 subtype of cancer cells and Anti-PD-1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\": \"Tumor\", \"variable_name\": \"T14b=PD1:aPD1\", \"units\": \"mole\", \"variable_definition\": \"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-1 expressed by Effector T cells that interact with the T14 subtype of cancer cells and Anti-PD-L1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\": \"Tumor\", \"variable_name\": \"C15a=PD1:aPD1\", \"units\": \"mole\", \"variable_definition\": \"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-1 expressed by the T15 subtype of cancer cells and Anti-PD-1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\": \"Tumor\", \"variable_name\": \"T15b=PD1:aPD1\", \"units\": \"mole\", \"variable_definition\": \"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-1 expressed by Effector T cells that interact with the T15 subtype of cancer cells and Anti-PD-L1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\": \"Tumor\", \"variable_name\": \"C16a=PD1:aPD1\", \"units\": \"mole\", \"variable_definition\": \"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-1 expressed by the T16 subtype of cancer cells and Anti-PD-1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\": \"Tumor\", \"variable_name\": \"T16b=PD1:aPD1\", \"units\": \"mole\", \"variable_definition\": \"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-1 expressed by Effector T cells that interact with the T16 subtype of cancer cells and Anti-PD-L1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\": \"Tumor\", \"variable_name\": \"T12b=PD1:aPD1\", \"units\": \"mole\", \"variable_definition\": \"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-1 expressed by Effector T cells that interact with the T12 subtype of cancer cells and Anti-PD-L1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\": \"Tumor\", \"variable_name\": \"TregT\", \"units\": \"cell\", \"variable_definition\": \"Total number of T Regulatory cells that able to engage with Effector T cells and mAPCs in the tumor\"}"
"{\"compartment_location\": \"Tumor\", \"variable_name\": \"TregT_Teff\", \"units\": \"cell\", \"variable_definition\": \"T Regulatory cells in the tumor that have engaged in interacting with Effector T cells\"}"
"{\"compartment_location\": \"Tumor\", \"variable_name\": \"MDSC_T\", \"units\": \"cell\", \"variable_definition\": \"Total number of MDSCs that able to engage with Effector T cells in the tumor\"}"
"{\"compartment_location\": \"Tumor\", \"variable_name\": \"MDSCsT_Teff\", \"units\": \"cell\", \"variable_definition\": \"MDSCs in the tumor that have engaged in interacting with Effector T cells\"}"
"{\"compartment_location\": \"Tumor\", \"variable_name\": \"MDSCsT_EngTeff\", \"units\": \"cell\", \"variable_definition\": \"MDSCs in the tumor that have engaged in interacting with Effector T cells that are accounting for the expression of PD-1 and PD-L1\"}"
"{\"compartment_location\": \"Tumor\", \"variable_name\": \"TregT_EngAPC\", \"units\": \"cell\", \"variable_definition\": \"T Regulatory cells in the tumor that have engaged in interacting with mAPCs that are accounting for the expression of CTLA-4\"}"
"{\"compartment_location\": \"Tumor\", \"variable_name\": \"mAPCT_EngTregT\", \"units\": \"cell\", \"variable_definition\": \"mAPCs in the tumor that have engaged in interacting with T Regulatory cells that are accounting for the expression of CD80 and CD86\"}"
"{\"compartment_location\": \"Tumor\", \"variable_name\": \"Teff_EngTregT\", \"units\": \"cell\", \"variable_definition\": \"Effector T cells in the tumor that have engaged in interacting with T Regulatory cells that are accounting for the expression of CD80, PD-1 and PD-L1\"}"
"{\"compartment_location\": \"Tumor\", \"variable_name\": \"PD1_TeffT\", \"units\": \"mole\", \"variable_definition\": \"PD-1 expressed by Effector T cells that interact with T Regulatory cells in the tumor\"}"
"{\"compartment_location\": \"Tumor\", \"variable_name\": \"PDL1_TeffT\", \"units\": \"mole\", \"variable_definition\": \"PD-L1 expressed by Effector T cells that interact with T Regulatory cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"CD80_TeffT\", \"units\":\"mole\", \"variable_definition\":\"CD80 expressed by Effector T cells that interact with T Regulatory cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"CD80_mAPCT\", \"units\":\"mole\", \"variable_definition\":\"CD80 expressed by mAPCs that interact with T Regulatory cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"PDL1_MDSCsT\", \"units\":\"mole\", \"variable_definition\":\"PD-L1 expressed by MDSCs that interact with Effector T cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"PD1_MDSCsT\", \"units\":\"mole\", \"variable_definition\":\"PD-1 expressed by MDSCs that interact with Effector T cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"CD86_mAPCT\", \"units\":\"mole\", \"variable_definition\":\"CD86 expressed by mAPCs that interact with T Regulatory cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"PD1_TregT\", \"units\":\"mole\", \"variable_definition\":\"PD-1 expressed by T Regulatory cells that interact with Effector T cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"PDL1_TregT\", \"units\":\"mole\", \"variable_definition\":\"PD-L1 expressed by T Regulatory cells that interact with Effector T cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"CTLA4_TregT\", \"units\":\"mole\", \"variable_definition\":\"CTLA-4 expressed by T Regulatory cells that interact with mAPCs in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"CTLA4:CD80_TrAT\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between CD80 expressed by mAPCs and CTLA-4 expressed on T Regulatory cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"CTLA4:CD86_TrAT\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between CD86 expressed by mAPCs and CTLA-4 expressed on T Regulatory cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"CTLA4_CTLA4-Trt\", \"units\":\"mole\", \"variable_definition\":\"Heterogeneous receptor-antibody interactions at the immunological synapse between CTLA-4 expressed by T Regulatory cells that interact with the mAPCs and Anti- PD-L1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"PDL1:PD1_TrTeff\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-1 expressed by the Effector T cells and PD-L1 expressed on T Regulatory cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"PDL1:CD80_TrTeff\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between CD80 expressed by the Effector T cells and PD-L1 expressed on T Regulatory cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"PD1:PDL1_TrTeff\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-L1 expressed by the Effector T cells and PD-1 expressed on T Regulatory cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"PDL1:CD80_MDSCT\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between CD80 expressed by the Effector T cells and PD-L1 expressed on MDSCs in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"PDL1:PD1_MDSCT\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-1 expressed by the Effector T cells and PD-L1 expressed on MDSCs cells in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"PD1:PDL1_MDSCT\", \"units\":\"mole\", \"variable_definition\":\"Receptor-receptor interactions at the immunological synapse between PD-L1 expressed by the Effector T cells and PD-1 expressed on MDSCs in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"PD1:aPD1_Teff\", \"units\":\"mole\", \"variable_definition\":\"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-1 expressed by Effector T cells that interact with the T Regulatory cells and Anti-PD-1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"PDL1:aPDL1_Teff\", \"units\":\"mole\", \"variable_definition\":\"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-L1 expressed by Effector T cells that interact with the T Regulatory cells and Anti-PD-L1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"PDL1:aPDL1_Treg\", \"units\":\"mole\", \"variable_definition\":\"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-L1 expressed by T Regulatory cells that interact with Effector T cells and Anti-PD-L1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"PD1:aPD1_Treg\", \"units\":\"mole\", \"variable_definition\":\"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-1 expressed by T Regulatory cells that interact with Effector T cells and Anti-PD-1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"PD1:aPD1_MDSCs\", \"units\":\"mole\", \"variable_definition\":\"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-1 expressed by MDSCs that interact with Effector T cells and Anti-PD-1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"PDL1:aPDL1_MDSCs\", \"units\":\"mole\", \"variable_definition\":\"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-L1 expressed by MDSCs that interact with Effector T cells and Anti-PD-L1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"TregT_EngTeff\", \"units\":\"cell\", \"variable_definition\":\"T Regulatory cells in the tumor that have engaged in interacting with Effector T cells that are accounting for the expression of PD-1 and PD-L1\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"Teff_EngMDSC\", \"units\":\"cell\", \"variable_definition\":\"Effector T cells in the tumor that have engaged in interacting with MDSCs that are accounting for the expression of CD80, PD-1 and PD-L1\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"CD80_TeffT1\", \"units\":\"mole\", \"variable_definition\":\"CD80 expressed by Effector T cells that interact with MDSCs in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"PDL1_TeffT1\", \"units\":\"mole\", \"variable_definition\":\"PD-L1 expressed by Effector T cells that interact with MDSCs in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"PD1_TeffT1\", \"units\":\"mole\", \"variable_definition\":\"PD-1 expressed by Effector T cells that interact with MDSCs in the tumor\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"PD1:aPD1_Teff1\", \"units\":\"mole\", \"variable_definition\":\"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-1 expressed by Effector T cells that interact with the MDSCs and Anti-PD- 1 mAb delivered to the tumor by way of IV injection into the blood\"}"
"{\"compartment_location\":\"Tumor\", \"variable_name\":\"PDL1:aPDL1_Teff1\", \"units\":\"mole\", \"variable_definition\":\"Heterogeneous receptor-antibody interactions at the immunological synapse between PD-L1 expressed by Effector T cells that interact with the MDSCs and Anti-PD- L1 mAb delivered to the tumor by way of IV injection into the blood\"}"